RT Journal Article
T1 Glycaemic efficacy and safety of linagliptin for the management of non-cardiac surgery patients with type 2 diabetes in a real-world setting: Lina-Surg study.
A1 Perez-Belmonte, Luis M
A1 Osuna-Sanchez, Julio
A1 Millan-Gomez, Mercedes
A1 Lopez-Carmona, Maria D
A1 Gomez-Doblas, Juan J
A1 Cobos-Palacios, Lidia
A1 Sanz-Canovas, Jaime
A1 Barbancho, Miguel A
A1 Lara, Jose P
A1 Jimenez-Navarro, Manuel
A1 Bernal-Lopez, M Rosa
A1 Gomez-Huelgas, Ricardo
K1 Diabetes mellitus
K1 Inpatient hyperglycaemia
K1 Linagliptin
K1 Non-cardiac surgery
AB Introduction: The use of dipeptidyl peptidase-4 inhibitors in hospitalized patients is an area of active research. We aimed to compare the efficacy and the safety of the basal-bolus insulin regimen versus linagliptin-basal insulin in non-critically ill non-cardiac surgery patients in a real-world setting. Methods: We enrolled patients with type 2 diabetes hospitalized in non-cardiac surgery departments with admission glycated haemoglobin level  200 mg/dL (p = .199), and treatment failures (p = .395). Total daily insulin and number of daily insulin injections were lower in the linagliptin-basal group (both p p < .001). Patients on linagliptin-basal insulin had fewer hypoglycaemicevents (blood glucose < 70 mg/dL) (p < .001).Conclusion: For type 2 diabetes surgery patients with mild to moderate hyperglycaemia with-out pre-hospitalization injectable therapies, linagliptin-basal insulin was an effective, safe alterna-tive with fewer hypoglycaemic events in real-world practice.
PB Taylor & Francis
YR 2019
FD 2019-05-21
LK http://hdl.handle.net/10668/13895
UL http://hdl.handle.net/10668/13895
LA en
NO Pérez-Belmonte LM, Osuna-Sánchez J, Millán-Gómez M, López-Carmona MD, Gómez-Doblas JJ, Cobos-Palacios L, et al. Glycaemic efficacy and safety of linagliptin for the management of non-cardiac surgery patients with type 2 diabetes in a real-world setting: Lina-Surg study. Ann Med. 2019 May-Jun;51(3-4):252-261
DS RISalud
RD Apr 9, 2025